Paul McCormac - Nov 7, 2023 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: Chief Technical Officer
Signature: /s/ Jenny Robertson, Attorney-in-Fact
Stock symbol: LXEO
Transactions as of: Nov 7, 2023
Transactions value $: $0
Form type: 4
Date filed: 11/9/2023, 08:35 PM
Previous filing: Nov 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXEO	Common Stock	Conversion of derivative security		+3.19K	+22.54%		17.3K	Nov 7, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXEO	Series B convertible preferred stock	Conversion of derivative security		-29.1K	-100%		0	Nov 7, 2023	Common Stock	3.19K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Content

Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.